Concept 1 of 71 min
Clinical trials and what they mean for value
A Phase III miss
| Value before Phase III | 600 |
|---|---|
| Patients | 3,000 |
| Primary endpoint | missed |
- 2 secondary endpoints met: not enough
- The programme is likely to stop
The drug's value falls towards zero, taking most of the company with it.
- Phase ISafety, in a few people
- Phase IIEfficacy and dose, in a few hundred
- Phase IIIEfficacy, in thousands, on the primary endpoint
- ApprovalThe drug can be sold
- Phase IVStudies after approval
Phase I tests a few people and Phase II a few hundred. Approval is judged on the pre-specified primary endpoint, and a Phase III failure usually wipes out most of the drug's value.
Phase IV follows approval.
Industry studies put the share of drugs entering Phase I that reach approval near 8% to 10%, lower in oncology. Each step is a gate: a missed primary endpoint, even with secondary endpoints met, rarely supports approval, so the programme usually ends and the risk-adjusted value collapses.
A single-asset biotech can lose most of its value in a day on such news.
- Mixing up the phases: efficacy in large groups is Phase III.
- Reading met secondary endpoints as enough for approval.
- Assuming a failed drug keeps its value through other uses.
A biotech announces that its Phase III trial missed its primary endpoint. What happens to its valuation, and why?
A complete answer covers
- Approval is judged on the pre-specified primary endpoint, so it becomes unlikely.
- The drug's risk-adjusted value collapses; development usually stops.
- A single-asset company can lose most of its value in a day.
- What is left: cash, other pipeline assets, possibly other indications.
Also in our technical interviews, on camera, with a score.
Concept 2 of 71 min
Valuing a pipeline: risk-adjusted NPV
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inConcept 3 of 71 min
Patents, exclusivity and generics
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inConcept 4 of 71 min
Biotech finance: runway, partners and deal terms
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inConcept 5 of 71 min
Drug prices and R&D
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inConcept 6 of 71 min
Healthcare services, outsourcing and medtech
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inConcept 7 of 71 min
AdvancedWhy a trial result can triple a biotech's value
The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.
See the plansSign inRecap
- Phase I tests safety, Phase II efficacy and dose, Phase III efficacy in thousands of patients; only about 1 drug in 10 entering Phase I is approved.
- Risk-adjusted NPV (net present value) = probability of approval × value if approved − development costs that are certain; probabilities of successive steps multiply.
- Generics take most of a small molecule's sales within a year or two of patent expiry; biosimilars erode biologics more slowly.
- Pharma is valued as a sum of the parts: marketed drugs by DCF (discounted cash flow) to their loss of exclusivity, pipeline by risk-adjusted NPV.
- Biotechs live on runway and partners: upfront, milestones and royalties; contingent value rights bridge disagreements on a pipeline.
25 questions on Healthcare and pharma
Timed, like the real one, drawn from a bank of 33. Every answer explained.